Viskase Holdings Inc
enzon.comWhat Do They Do?
Makes cellulosic, fibrous and plastic casings for processed meat and poultry makers, and provides product support services to food companies.
10-K for FY2025, filed Mar 2, 2026 8-K, filed Mar 26, 2026On June 20, 2025, the Company, EPSC Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of ours (“Merger Sub”), and…View ↗
Viskase is a leading worldwide producer of non-edible cellulosic, fibrous and plastic casings used to prepare and package processed meat…View ↗
Who Are Their Customers?
Its casing products and support services serve customers in processed meat and poultry, including some of the world's largest global consumer products companies.
8-K, filed Mar 26, 2026Viskase is a leading worldwide producer of non-edible cellulosic, fibrous and plastic casings used to prepare and package processed meat…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 3, 2026
−$5.1MView ↗
- ▼ −75% (Loss)
- vs −$20.2M in Q2 FY2025
-
Apr 16, 2026
Replaced Enzon's auditor with Grant Thornton
Grant Thornton was appointed to audit the company's fiscal 2026 financial statements, subject to completion of acceptance procedures.
Sources
8-K, filed Apr 16, 2026
On April 14, 2026, the Audit Committee of the Company appointed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent…View ↗
-
Apr 15, 2026
Appointed Michael Blecic as chief financial officer
Blecic's appointment took effect on April 10, 2026.
Sources
8-K, filed Apr 15, 2026
On April 10, 2026, the Board of Directors (the “Board”) of Viskase Holdings, Inc. (the “Company”) appointed Michael Blecic to serve as the…View ↗
-
Mar 26, 2026
Completed the Viskase merger and changed the company's name
Viskase became a wholly owned subsidiary, and Thomas D. Davis became chief executive.
Sources
8-K, filed Mar 26, 2026
On March 26, 2026 (the “Closing Date”), Viskase Holdings, Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the “Company” or the…View ↗
Vicineum licensing
The earlier report described a marketing agreement that could generate milestone and royalty payments if the drug were approved. The latest report says the license was canceled and does not expect future revenue from it.
10-K for FY2022, filed Feb 16, 2023 10-K for FY2025, filed Mar 2, 2026Historically, we have received royalty revenues from licensing arrangements with other companies primarily related to sales of certain drug…View ↗
Loading...
